Nektar Therapeutics (NKTR) Chief R&D Officer Jonathan Zalevsky Sells Shares

What Happened

• Jonathan Zalevsky, Chief Research & Development Officer of Nektar Therapeutics (NKTR), sold 5,538 shares in an open‑market transaction on June 15, 2026. The weighted average sale price was $60.71 per share, for total proceeds of approximately $336,212. This was a sale (not a purchase), executed pursuant to a pre‑arranged trading plan.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (no late filing indicated).
• Shares sold: 5,538; weighted average price: $60.71; total value: ~$336,212.
• Price range: individual trades executed between $60.06 and $61.36 (weighted average reported).
• Footnote: Sale was made under a Rule 10b5‑1 trading plan adopted March 13, 2026; reporting person will provide detailed trade-by-trade prices/quantities on request.
• Shares owned after transaction: not specified in the provided filing.

Context

• A 10b5‑1 plan allows insiders to sell shares according to a pre‑set schedule and is commonly used to avoid trading based on nonpublic information; such sales are often routine and do not by themselves indicate management sentiment about the company.